BlackRock’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-3,791,801
| Closed | -$285M | – | 6026 |
|
|
2022
Q2 | $285M | Buy |
3,791,801
+99,587
| +3% | +$4.43M | 0.01% | 1266 |
|
|
2022
Q1 | $99.1M | Sell |
3,692,214
-91,111
| -2% | -$3.06M | ﹤0.01% | 2144 |
|
|
2021
Q4 | $180M | Buy |
3,783,325
+32,589
| +0.9% | +$1.46M | ﹤0.01% | 1813 |
|
|
2021
Q3 | $249M | Sell |
3,750,736
-104,467
| -3% | -$7.44M | 0.01% | 1548 |
|
|
2021
Q2 | $301M | Buy |
3,855,203
+677,558
| +21% | +$50.1M | 0.01% | 1472 |
|
|
2021
Q1 | $301M | Buy |
3,177,645
+20,258
| +0.6% | +$2.41M | 0.01% | 1415 |
|
|
2020
Q4 | $385M | Buy |
3,157,387
+454,506
| +17% | +$49.8M | 0.01% | 1090 |
|
|
2020
Q3 | $236M | Buy |
2,702,881
+411,851
| +18% | +$28.7M | 0.01% | 1257 |
|
|
2020
Q2 | $148M | Buy |
2,291,030
+180,161
| +9% | +$10.4M | 0.01% | 1578 |
|
|
2020
Q1 | $94.3M | Sell |
2,110,869
-19,962
| -0.9% | -$1.06M | ﹤0.01% | 1680 |
|
|
2019
Q4 | $133M | Buy |
2,130,831
+1,414,535
| +197% | +$67.3M | 0.01% | 1784 |
|
|
2019
Q3 | $26.9M | Buy |
716,296
+138,408
| +24% | +$6.03M | ﹤0.01% | 2649 |
|
|
2019
Q2 | $23.5M | Buy |
+577,888
| New | +$20.6M | ﹤0.01% | 2759 |
|
BlackRock's TPTX Position: Q3 2022 in Review
BlackRock sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 3,791,801 shares — an estimated $285M sold.
BlackRock first reported a position in TPTX in Q2 2019 and held it in 13 quarters. The position peaked at $385M in Q4 2020. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.
- BlackRock reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
- BlackRock sold 3,791,801 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $285M.
- BlackRock first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2019 and held it in 13 quarters.
- BlackRock's Turning Point Therapeutics, Inc. Common Stock position peaked at $385M in Q4 2020.
- 0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.
Based on BlackRock's 13F filing for Q3 2022, filed 14 Nov 2022.